Deferasirox | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Deferasirox
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

Zhejiang Hengkang Deferasirox

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Deferasirox

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

73 API Suppliers, 24 USDMF, 11 CEP/COS, 1 JDMF, 24 EU WC, 16 KDMF, 19 NDC API, 52 Listed Suppliers, $ API Reference Price

73 API Suppliers
24 USDMF
11 CEP/COS
1 JDMF
24 EU WC
16 KDMF
19 NDC API
52 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

31 Intermediate Suppliers

31 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

378 FDF Dossiers, 108 FDA Orange Book, 46 Europe, 33 Canada, 144 Australia, 5 South Africa, 42 Listed Dossiers

378 FDF Dossiers
108 FDA Orange Book
46 Europe
33 Canada
144 Australia
5 South Africa
42 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

GRANULE;ORAL - 180MG, GRANULE;ORAL - 360MG, GRANULE;ORAL - 90MG

GRANULE;ORAL - 180MG
GRANULE;ORAL - 360MG
GRANULE;ORAL - 90MG

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 1 DKSH, 3 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 6 BASF, 4 DFE Pharma, 4 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 17 Kerry, 9 Microlex e.U, 1 Nanjing Bold Chemical, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 2 Prachin Chemical, 7 Roquette, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 9 Sigachi Industries, 1 Ulanqab Kema New Material, 2 Vasa Pharmachem

1 SPI Pharma
1 DKSH
3 Faran Shimi Pharmaceutical
3 Boai NKY Pharmaceuticals Ltd
3 Gangwal Healthcare
2 Nanjing Well Pharmaceutical
3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
6 BASF
4 DFE Pharma
4 Gangwal Chemicals
1 Ideal Cures Pvt Ltd
17 Kerry
9 Microlex e.U
1 Nanjing Bold Chemical
1 Pharmatrans-Sanaq
3 Pluviaendo
2 Prachin Chemical
7 Roquette
3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shanghai Welltone Material Technology Co., Ltd
9 Sigachi Industries
1 Ulanqab Kema New Material
2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Fillers, Diluents & Binders, 13 Lubricants & Glidants, 13 Direct Compression, 12 Granulation, 11 Thickeners and Stabilizers, 9 Co-Processed Excipients, 4 Coating Systems & Additives, 4 Disintegrants & Superdisintegrants, 4 Taste Masking, 4 Emulsifying Agents, 4 Controlled & Modified Release, 2 Chewable & Orodispersible Aids, 2 Parenteral, 2 Film Formers & Plasticizers, 2 API Stability Enhancers, 2 Solubilizers, 2 Topical, 1 Surfactant & Foaming Agents, 1 Rheology Modifiers

39 Fillers, Diluents & Binders
13 Lubricants & Glidants
13 Direct Compression
12 Granulation
11 Thickeners and Stabilizers
9 Co-Processed Excipients
4 Coating Systems & Additives
4 Disintegrants & Superdisintegrants
4 Taste Masking
4 Emulsifying Agents
4 Controlled & Modified Release
2 Chewable & Orodispersible Aids
2 Parenteral
2 Film Formers & Plasticizers
2 API Stability Enhancers
2 Solubilizers
2 Topical
1 Surfactant & Foaming Agents
1 Rheology Modifiers

DIGITAL CONTENT

59 NEWS #PharmaBuzz

59 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 42 Finished Drug Prices, 9 Annual Reports

3 US Medicaid Prescriptions
42 Finished Drug Prices
9 Annual Reports

MARKET PLACE

10 APIs, 3 FDF Dossiers

10 APIs
3 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 US Patents, 6 Health Canada Patents

3 US Patents
6 Health Canada Patents

REF. STANDARDS & IMPURITIES

16 Others

16 Others

$ API Ref.Price (USD/KG) : 401 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 6Gowling WLG (Canada) LLP

filter Patent Reset all filters

6 All

01 62255951

filter Product Reset all filters

6 All

01 3DEFERASIROX

02 3Deferasirox

filter Dosage Reset all filters

6 All

01 1Dispersible Tablet for Oral Suspension

02 2Dispersible Tablets for Oral Suspension

03 3TABLET

filter Exp Date Reset all filters

6 All

01 62017-06-24

Synnat Deferasirox

Product Main Page

01

Gowling WLG (Canada) LLP

Deferasirox

The Generic Rx Session

Not Confirmed

Gowling WLG (Canada) LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Deferasirox

Brand Name : EXJADE

Patent Number : 2255951

Filing Date : 1997-06-24

Strength per Unit : 125 mg

Dosage Form : Dispersible Tablet for Oral Suspension

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling WLG (Canada) LLP

Deferasirox

The Generic Rx Session

Not Confirmed

Gowling WLG (Canada) LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Deferasirox

Brand Name : EXJADE

Patent Number : 2255951

Filing Date : 1997-06-24

Strength per Unit : 250 mg

Dosage Form : Dispersible Tablets for Oral Suspension

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Gowling WLG (Canada) LLP

Deferasirox

The Generic Rx Session

Not Confirmed

Gowling WLG (Canada) LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Deferasirox

Brand Name : EXJADE

Patent Number : 2255951

Filing Date : 1997-06-24

Strength per Unit : 500 mg

Dosage Form : Dispersible Tablets for Oral Suspension

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Gowling WLG (Canada) LLP

Deferasirox

The Generic Rx Session

Not Confirmed

Gowling WLG (Canada) LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Deferasirox

Brand Name : JADENU

Patent Number : 2255951

Filing Date : 1997-06-24

Strength per Unit : 360 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Gowling WLG (Canada) LLP

Deferasirox

The Generic Rx Session

Not Confirmed

Gowling WLG (Canada) LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Deferasirox

Brand Name : JADENU

Patent Number : 2255951

Filing Date : 1997-06-24

Strength per Unit : 90 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Gowling WLG (Canada) LLP

Deferasirox

The Generic Rx Session

Not Confirmed

Gowling WLG (Canada) LLP

Canada

The Generic Rx Session

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Deferasirox

Brand Name : JADENU

Patent Number : 2255951

Filing Date : 1997-06-24

Strength per Unit : 180 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2017-06-24

Date Granted : 2006-10-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!